Recruiting

Chemotherapy plus immune-boosting drug and surgery for early-stage cervical cancer

Plain-English translation of NCT06289751 on ClinicalTrials.gov ↗ · Source last updated September 2024 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new approach to treating early-stage cervical cancer (specifically stage IB2) using a combination of chemotherapy, a medication called cadunilizumab that helps boost your immune system to fight cancer, followed by surgery to remove the uterus. The goal is to see if this combination can work as well as traditional surgery alone while potentially reducing the serious side effects that can affect quality of life, such as nerve damage, urinary problems, and sexual dysfunction.

Standard treatment for early cervical cancer involves major surgery to remove the uterus and surrounding tissue, but this operation carries significant risks of complications and long-term problems with bladder, bowel, and sexual function—especially for younger patients. Researchers hope that using chemotherapy and this immune-boosting treatment before a less extensive surgery might achieve the same cancer control with fewer of these serious side effects.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with stage IB2 cervical cancer (as defined by current medical staging standards) and have not received any prior cancer treatment
your cancer shows positive PD-L1 expression (a specific marker found in lab tests)
you are between 18 and 70 years old
you have adequate blood cell counts and normal kidney, liver, and bile duct function based on recent blood tests
you have at least one measurable tumor lesion that can be seen on imaging such as an MRI

You likely don't qualify if…

you have an active or recent autoimmune disease (with some exceptions for well-controlled conditions like thyroid disease or asthma that resolved in childhood)
you have received any prior immune checkpoint inhibitor medications or other immunotherapy drugs
you are currently taking high-dose corticosteroids or immunosuppressive medications
you have an active systemic infection or a serious infection requiring hospitalization within the past 4 weeks
you have untreated chronic hepatitis B or C with active viral infection

What participation looks like

You would receive chemotherapy given by intravenous infusion, followed by doses of cadunilizumab (the immune-boosting medication), and then undergo surgery to remove your uterus. Throughout this process, you would have regular clinic visits for blood tests, imaging scans, and physical exams to monitor how you are responding to treatment and to manage any side effects. The trial involves 50 patients total, and you would be closely followed by the research team to track your recovery and long-term outcomes.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Trial locations(2 sites)

China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Qilu Hospital of Shandong University, Jinan, Shandong